ReviewFrontiers in toxicology2023
How safe are nanoscale metal-organic frameworks?
Review in Frontiers in toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Hierarchical Environmental Exposure Transforms Zeolitic Imidazolate Framework-8 and Increases Toxicity inACS nano · 2026Article
- EGCG-Building Nanocarriers for Multitasking Drug Delivery: Design Principles, Therapeutic Opportunities, and Translational Challenges.International journal of nanomedicine · 2026Review
- Importance of control experiments in toxicity test of metal-organic frameworks: Recent advances and challenges.Eco-Environment & Health · 2025Review
- Biomolecular Transformations Shape the Environmental Fate of Nanoscale and Emerging Materials.Accounts of chemical research · 2025Review
- Multiscale Profiling of Nanoscale Metal-Organic Framework Biocompatibility and Immune Interactions.Advanced healthcare materials · 2025Article
- Advanced Metal-Organic Framework-Based Sensor Systems for Gas and Environmental Monitoring: From Material Design to Embedded Applications.Sensors (Basel, Switzerland) · 2025Review
- Metal-organic frameworks as thermocatalysts for hydrogen peroxide generation and environmental antibacterial applications.Science advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to the size scales that can be accessed, the nanoscale has opened doors to new physical and chemical properties, not seen in the bulk. These properties are leveraged by nanomaterials (NMs) across a plethora of applications. More recently, nanoscale metal-organic frameworks (nMOFs) have witnessed explosive growth due to the modularity of their chemical constituents, the ability to modify their composition and structure, and exceptional properties such as permanent porosity and high surface areas. These properties have prompted the investigation of these materials for applications in biological and environmental contexts. However, one aspect that is often ignored in these discussions is their safety at a nanoscale. In this mini review, we aim to initiate a discussion on the safety and toxicity of nMOFs, drawing parallels with the existing guidelines and literature on the safety of inorganic NMs. We first describe why nMOFs are of considerable interest to the scientific community followed by a discussion on routes through which they can be exposed to the environment and living organisms, particularly shedding light on their transformation mechanisms. The review also discusses the factors affecting toxicity of nMOFs, such as their size, shape, morphology, and composition. We briefly highlight potential mechanisms of toxicity and conclude with describing the need to transition towards data-intensive computational approaches such as machine learning to establish nMOFs as credible materials for their envisioned applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.